Brief: Abliva Reports Positive Clinical Results For PMD Drug

Abliva AB

20/05/2021 06:50

May 20 (Reuters) - Abliva AB  ABLI.ST 
    * ANNOUNCED ON WEDNESDAY POSITIVE SAFETY AND PHARMACOKINETIC
DATA
FROM THE DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 1A/B
STUDY WITH KL1333
    * CO ALSO REPORTS SIGNALS OF EFFICACY IN RELEVANT CLINICAL
OUTCOME
MEASURES IN PATIENTS WITH PRIMARY MITOCHONDRIAL DISEASES
    * PRIMARY AIM OF STUDY WAS TO ASSESS SAFETY AND
PHARMACOKINETICS
OF KL1333, CO’S CANDIDATE DRUG FOR CHRONIC ORAL TREATMENT OF PMD

    
    
 Source text for Eikon:  urn:newsml:reuters.com:*:nMFN9hTyTk
    
 Further company coverage:  ABLI.ST  
   


 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))